抗VEGF与激光光凝治疗早产儿视网膜病变的神经发育结局:美国眼科学会报告
该报告系统综述了抗VEGF与激光光凝作为早产儿视网膜病变初始治疗后的神经发育结局,纳入26项研究(含4项RCT)。多数研究(77%)未发现两组神经发育差异有统计学意义;仅5项研究评估4岁以上智商,均未发现显著差异。尚无Ⅰ级证据,且无研究针对神经发育结局进行功效计算。
要点
- 多数研究未显示抗VEGF与激光光凝在神经发育结局上有显著差异。
- 仅5项研究评估4岁以上智商,均未发现组间显著差异。
- 无研究针对神经发育结局进行功效计算,证据级别有限。
核心结论
- 系统综述Ⅱ级和Ⅲ级证据显示,抗VEGF与激光光凝作为ROP初始治疗后的神经发育结局无差异证据。
研究设计与样本
- 文献检索于2025年12月在PubMed进行,无日期限制,限英文,获52篇,26篇纳入。
- 纳入4篇RCT(Ⅱ级证据)和22篇比较性队列研究(Ⅲ级证据)。
- 研究覆盖2006至2022年17年间39个国家的婴儿。
- 最常用神经发育测试为Bayley婴幼儿发育量表,用于13项研究(50%)。
- 评估年龄从矫正年龄0个月至12岁,多数研究(14项[54%])测试小于24月龄婴儿。
主要发现
- 20项研究(77%),包括所有RCT,未检测到抗VEGF与激光光凝在神经发育结局上有统计学显著差异。
- 4项研究发现接受玻璃体腔注射贝伐珠单抗(IVB)初始治疗的婴儿神经发育结局更差。
- 2项研究发现接受激光光凝初始治疗的婴儿神经发育结局更差。
- 5项研究(19%)包含4岁以上智商测试,均未检测到抗VEGF(4项IVB,1项雷珠单抗)与激光光凝在智商上有统计学显著差异。
关键数值与推荐
- 纳入26项研究:4篇RCT为Ⅱ级证据,22篇比较性队列研究为Ⅲ级证据。
- 多数研究(20项[77%])未发现神经发育结局的统计学显著差异。
- 仅5项研究(19%)评估4岁以上智商,均未发现显著差异。
临床怎么用
- 临床决策时可参考:现有证据未显示抗VEGF与激光光凝在神经发育结局上有显著差异。
- 需注意证据级别为Ⅱ-Ⅲ级,且无研究针对神经发育结局进行功效计算。
局限性
- 无Ⅰ级证据可用。
- 无研究针对神经发育结局或检测小差异进行功效计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the evidence on neurodevelopmental outcomes after intravitreal anti-VEGF compared with laser photocoagulation surgery (LPC) for primary treatment of retinopathy of prematurity (ROP). METHODS: A literature search was last conducted in the PubMed database in December 2025 without date restrictions and limited to articles published in English. The search yielded 52 articles, 26 of which met criteria for inclusion. The panel methodologist assigned ratings to the articles according to the level of evidence. RESULTS: Of the 26 articles included, 4 articles on 3 randomized controlled trials (RCTs) were rated level II evidence and 22 comparative cohort studies were rated level III evidence. The studies included infants who were treated and followed over a 17-year period from 2006 through 2022 in 39 countries. The most common neurodevelopmental test used was the Bayley Scales of Infant and Toddler Development, used in 13 studies (50%). The age at assessment ranged from 0 months corrected age to 12 years, where most studies (n = 14 [54%]) included testing of infants younger than 24 months of age. Most studies (n = 20 [77%]), including all RCTs, did not detect a statistically significant difference in neurodevelopmental outcomes after anti-VEGF compared with LPC for primary treatment of ROP. Neurodevelopmental outcomes were found to be worse among those infants treated with intravitreal bevacizumab (IVB) for primary treatment in 4 studies and among those treated with LPC for primary treatment in 2 studies. Only 5 studies (19%) included intelligence quotient (IQ) testing beyond 4 years of age, and none detected a statistically significant difference in IQ between those who received anti-VEGF (IVB in 4 studies and intravitreal ranibizumab in 1 study) compared with those who received LPC for primary treatment of ROP. CONCLUSIONS: Although no level I evidence was available, systematically reviewed studies with level II and III evidence showed no evidence that neurodevelopmental outcomes differed among infants who received anti-VEGF compared with LPC for primary treatment of ROP. A limitation to this assessment was that no study was powered for neurodevelopmental outcomes or to detect small differences in neurodevelopmental outcomes. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Prakalapakorn SG, Trivedi RH, Cavuoto KM, et al. Anti-VEGF versus Laser Photocoagulation Surgery for Primary Treatment of Retinopathy of Prematurity: Neurodevelopmental Outcomes: A Report by the American Academy of Ophthalmology. Ophthalmology. 2026. PMID: 42489607. doi:10.1016/j.ophtha.2026.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。